REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
03/02/2026
Back to search
Official data from USPTO
SAGASEQ
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
SAGASEQ
ST13
US500000079287897Class
5, 42, 44
Filing
79287897
Registration
6279624
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
40
Latest update
03/03/2026
Trademark type
Word
Nice classes
5, 42, 44
Filing date
03/05/2020
Registration date
03/02/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/02/2021
Last transaction
03/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
SE
Examiner
GLASSER, CARYN
Law office
L50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
SAGA Diagnostics AB
Representatives
Sarah J. Schneider Sheridan Ross P.C.
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Nucleic acid sequences for medical and veterinary purposes; reagents for use in medical genetic testing; reagents for use in veterinary genetic testing; diagnostic preparations and materialsmedical diagnostic reagents; chemical preparations for testing blood for medical purposes; chemical preparations for use in DNA analysis for medical purposes; chemical reagents for medical or veterinary purposes; chemical reagents for medical use; chemical reagents for veterinary use; chemical test reagents for medical purposes; chemical test reagents for veterinary purposes; clinical medical reagents; diagnostic agents for medical use; diagnostic biomarker reagents for medical purposes; diagnostic chemical reagents for medical use; diagnostic preparations for medical or veterinary purposes; diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; diagnostic reagents for medical use; diagnostic testing materials for medical use; genetic identity tests comprised of reagents for medical purposes; in vitro diagnostic preparations for medical use; medical diagnostic reagents and assays for testing of body fluids; medical diagnostic test strips for analysis of blood and other liquids; preparations for detecting genetic predispositions for medical purposes; preparations for detecting mutation in prion genes for medical purposes; reactants for medical diagnosis being diagnostic reagents for medical purposes; reagents and media for medical and veterinary diagnostic purposes; reagents for analytical purposes for medical purposes; reagents for analytical purposes for veterinary purposes; reagents for blood grouping for medical purposes; reagents for in-vitro laboratory use for medical purposes; reagents for in-vitro laboratory use for veterinary purposes; reagents for microbiological analysis for medical purposes; reagents for microbiological analysis for veterinary purposes; reagents for use in analysis for medical purposes; reagents for use in analysis for veterinary purposes; reagents for use in diagnostic tests for medical purposes; reagents for use in diagnostic tests for veterinary purposes; reagents for use with analyzers for medical purposes; reagents for use with analyzers for veterinary purposes; reagents for use in diagnostic pregnancy tests; veterinary diagnostic reagents
Class 42
Analysis of human serum for medical research; analysis of human tissues for medical research; biological researchclinical research in the field of cancer and infectious diseases and medical research; clinical research in the field of cancer and infectious diseases; clinical trials for others; conducting early evaluations in the field of new pharmaceuticals; consultancy relating to laboratory testing; consultancy relating to pharmaceutical research and development; medical laboratory services; medical research; medical research laboratory services; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical research and development; providing information about the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing scientific information in the field of medical disorders and their treatment; provision of information and data relating to medical and veterinary pharmaceutical and diagnostic research and development; research and development for the pharmaceutical industry; research and development in the pharmaceutical and biotechnology fields; scientific research and development; scientific research for medical purposes in the area of cancerous diseases; services for assessing the efficiency of pharmaceuticals; services for assessing the efficiency of veterinary drugs
Class 44
Genetic counseling; genetic testing of animals for diagnostic or treatment purposes; laboratory analysis being medical analysis for diagnostic and treatment of persons provided by medical laboratories; medical and healthcare services; medical monitoring of patients; stem cell therapy services; medical services; analysis of human serum for medical treatment; analysis of human tissues for medical treatment; blood bank services; bowel cancer screening services; breast cancer screening services; cervical cancer screening services; colonoscopy screening services; medical consultancy and information services relating to medical products; DNA screening for medical purposes; genetic testing for medical purposes; hepatitis screening services; lung cancer screening services; medical advice in the field of pregnancy; medical analysis for the diagnosis and treatment of persons relating to cancer and infectious diseases; medical analysis services for the diagnosis of cancer; medical analysis services for cancer diagnosis and prognosis; medical analysis services for the diagnosis of cancer; medical analysis services relating to the treatment of patients relating to cancer and infectious diseases; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical analysis services relating to the treatment of persons for cancer and infectious diseases provided by a medical laboratory; medical and health services relating to DNAgenetics and genetic testing; medical care and analysis of cancer diagnosis relating to patient treatment; medical consultations; medical diagnostic services; medical evaluation services; medical analysis services for diagnostic and treatment purposes of blood samples taken from patients provided by medical laboratories; medical screening; medical services for the treatment of skin cancer; medical services in the field of oncology; medical testing for diagnostic or treatment purposes; medical testing services relating to the diagnosis and treatment of disease; prostate cancer screening services; providing cancer screening services; providing news and information in the field of medicine; RNA or DNA analysis for cancer diagnosis and prognosis; services for the testing of blood; services for the testing of sera; services for the testing of urine; services for the preparation of medical reports relating to health care; technical consultancy services relating to medical health; testicular cancer screening services
Publications
History of USPTO decisions and trademark events.
40 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/24/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/15/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/15/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
12/15/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/15/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/15/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/15/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/21/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/28/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/03/2021
FIMP
FINAL DISPOSITION PROCESSED
06/03/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/02/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
03/02/2021
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
01/26/2021
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
01/14/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/15/2020
PUBO
PUBLISHED FOR OPPOSITION
12/15/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/25/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/13/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/11/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
11/11/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/11/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
11/11/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/11/2020
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
11/11/2020
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
09/08/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/21/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/20/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/19/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/19/2020
RFNT
REFUSAL PROCESSED BY IB
08/14/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/27/2020
RFRR
REFUSAL PROCESSED BY MPU
07/27/2020
MAFR
APPLICATION FILING RECEIPT MAILED
06/23/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/21/2020
CNRT
NON-FINAL ACTION WRITTEN
06/20/2020
DOCK
ASSIGNED TO EXAMINER
06/19/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/19/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/18/2020
Continuous trademark protection
Get notified about every new filing that threatens SAGASEQ or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.